Corixa Corporation

Immunex Corporation

Sterling Winthrop Inc.

Other

Children's Medical Center Corporation

Glaxosmithkline Biologicals Sa

Fundacao Butantan

Path Vaccine Solutions

Mark R Alderson

Yasir A Skeiky

Steven G Reed

Antonio Campos-Neto

Davin C Dillon

Richard Jeffrey Armitage

Raymond G Goodwin

Melanie K Spriggs

Craig A Smith

David Haskett Lynch

Yasir A W Skeiky

Kenneth H Grabstein

Jeffrey I Cohen

Michael R Comeau

Theresa M Farrah

Jean-Francois Lucien Maisonneuve

Lindsey M Hutt-Fletcher

William Christian Fanslow, Iii

Richard Malley

Yingjie Lu

Peter Probst

Ajay Bhatia

Martine Marchand

Zhengbin Yao

Yves Lobet

Pascal Mettens

JoDee Zappone

Brenda Maisonneuve

Porter Anderson

Florence Bernadette Nozay

George A Robertson

Antonio Campos-Nero

Andrea Maria Tate

Waldely De Oliveira Dias

Viviane Maimoni Gonçalves

Yasir Aw Skeiky

The present invention provides for immunogenic compositions and methods for producing an immunogenic composition with multiple immunity-inducing fractions of killed, whole-cellby selectively disrupting a whole cell bacterial preparation in such a manner that a soluble fraction that induces a primarily antibody response, and a cellular fraction that induces a primarily antibody-independent response, remain in the immunogenic composition.

Selectively disrupted whole-cell vaccine

The present invention relates to compositions comprising proteins or polynucleotides ofsp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis ofinfection.

Vaccines against chlamydial infection

The present invention relates to fusion proteins containing at least twoantigens. In particular, it relates to bi-fusion proteins which contain two individualantigens, tri-fusion proteins which contain threeantigens, tetra-fusion proteins which contain fourantigens, and penta-fusion proteins which contain fiveantigens, and methods for their use in the diagnosis, treatment and prevention of tuberculosis infection.

[object Object]

The present invention relates to compositions and fusion proteins containing at least twosp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and prevention of tuberculosis infection.

Fusion proteins of mycobacterium tuberculosis

The present invention relates to compositions and fusion proteins containing at least twosp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera from individuals infected with, and methods for their use in the diagnosis, treatment, and prevention ofinfection.

Novel 4-1BB ligand (4-1BB-L) polypeptides and a human cell surface receptor designated 4-1BB that binds 4-1BB-L are provided. Isolated 4-1BB-L-encoding and human 4-1BB-encoding DNA sequences, recombinant expression vectors comprising the isolated DNA sequences, and host cells transformed with the recombinant expression vectors are disclosed, along with methods for producing the novel polypeptides by cultivating such transformed host cells. Soluble forms of the 4-1BB-L or 4-1BB polypeptides are derived from the extracellular domains thereof.

Antibodies to human 4-1BB

The present invention relates to fusion proteins ofantigens. In particular, it relates to two fusion proteins, each of which contains three individualantigens, and a fusion protein of twoantigens, their coding sequences, and methods for their use in the treatment and prevention of tuberculosis.

Fusion proteins of mycobacterium tuberculosis antigens and their uses

Fusion proteins of Mycobacterium tuberculosis antigens and their uses

The present invention relates to fusion proteins containing at least two antigens. In particular, it relates to bi-fusion proteins which contain two individual antigens, tri-fusion proteins which contain three antigens, tetra-fusion proteins which contain four antigens, and penta-fusion proteins which contain five antigens, and methods for their use in the diagnosis, treatment and prevention of tuberculosis infection.

Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and/or pharmaceutical compositions for immunization against infection, or may be used for the diagnosis of tuberculosis.

Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use

Growing community of inventors

Bainbridge Island, WA, United States of America

Mark R Alderson